STOCK TITAN

NeuroSense Therapeutics Ltd. (NRSN) Financials

NRSN NASDAQ
FY2025 annual
Net Income -$11.1M n/m YoY
EPS (Diluted) -$0.44 n/m YoY
Free Cash Flow -$7.7M n/m YoY
Operating Cash Flow -$7.7M n/m YoY
Market Cap $2.4M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book n/m negative shareholder equity, so no book multiple, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NRSN SEC filings page.

This page shows NeuroSense Therapeutics Ltd. (NRSN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for NeuroSense Therapeutics Ltd., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

NeuroSense Therapeutics Ltd. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

NeuroSense Therapeutics Ltd. reported a net loss of $11.1M while operations used $7.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$11.1M
YoYn/m

NeuroSense Therapeutics Ltd.'s EBITDA was -$11.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$11.1M
YoYn/m

NeuroSense Therapeutics Ltd. reported a net loss of $11.1M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$0.44
YoYn/m

NeuroSense Therapeutics Ltd. earned -$0.44 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$7.7M
YoYn/m

NeuroSense Therapeutics Ltd. recorded an outflow of $7.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$166K
YoY-95.1%

NeuroSense Therapeutics Ltd. held $166K in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
33M
YoY+40.2%

NeuroSense Therapeutics Ltd. had 33M shares outstanding in fiscal year 2025. This represents an increase of 40.2% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

None of these metrics is reported for fiscal year 2025.

Capital Allocation

R&D Spending
$6.2M
YoY+9.3%

NeuroSense Therapeutics Ltd. invested $6.2M in research and development in fiscal year 2025. This represents an increase of 9.3% from the prior year.

Capital Expenditures
$8K
YoY+166.7%

NeuroSense Therapeutics Ltd. invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 166.7% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

NRSN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NRSN annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-F
R&D Expenses$6.2M+9.3%$5.7M-21.7%$7.3M+30.2%$5.6M+300.8%$1.4M
SG&A Expenses$4.9M+15.6%$4.2M-12.0%$4.8M-3.9%$5.0M+212.2%$1.6M
Operating Income-$11.1Mn/m-$9.9Mn/m-$12.0Mn/m-$10.6Mn/m-$3.0M
EBITDA-$11.1Mn/m-$9.9Mn/m-$12.0Mn/m-$10.5Mn/m-$3.0M
Net Income-$11.1Mn/m-$10.2Mn/m-$10.1Mn/m-$10.5Mn/m-$3.2M
EPS (Basic)-$0.44n/m-$0.54n/m-$0.74n/m-$0.91-$0.52
EPS (Diluted)-$0.44n/m-$0.54n/m-$0.74n/m-$0.91-$0.52
Diluted Shares (Avg)25M+37.0%19M+36.4%14M+18.6%12MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

NRSN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NRSN annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-F
Total Assets$1.0M-77.5%$4.6M+43.6%$3.2M-58.7%$7.7MN/A
Current Assets$778K-82.3%$4.4M+51.0%$2.9M-60.5%$7.4MN/A
Cash & Equivalents$166K-95.1%$3.4M+28.0%$2.6M-25.5%$3.5M-68.0%$11.1M
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0
Total Liabilities$2.6M+29.9%$2.0M-59.7%$4.9M+164.0%$1.9MN/A
Current Liabilities$2.5M+26.3%$2.0M-42.4%$3.5M+100.4%$1.7MN/A
Non-Current Liabilities$72Kn/m$0-100.0%$1.5M+910.2%$147KN/A
Total Equity-$1.6M-160.4%$2.6Mn/m-$1.8M-130.1%$5.8M-46.1%$10.8M
Retained Earnings-$47.8Mn/m-$36.7Mn/m-$26.1Mn/m-$16.0MN/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NRSN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NRSN annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-F
Operating Cash Flow-$7.7Mn/m-$10.1Mn/m-$8.4Mn/m-$7.6Mn/m-$1.5M
Depreciation & Amortization$16K-27.3%$22K+4.8%$21K+75.0%$12K+300.0%$3K
Stock-Based Compensation$2.1M+284.2%$557K-63.8%$1.5M-11.1%$1.7M+42.0%$1.2M
Capital Expenditures$8K+166.7%$3K-89.7%$29K-58.6%$70K+311.8%$17K
Free Cash Flow-$7.7Mn/m-$10.1Mn/m-$8.4Mn/m-$7.7Mn/m-$1.6M
Investing Cash Flow-$8K-900.0%$1K-100.0%$3.5Mn/m-$3.6Mn/m-$17K
Financing Cash Flow$4.4M-59.4%$10.9M+174.5%$4.0M+5.3%$3.8M-68.3%$11.9M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NRSN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NRSN annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-F
Return on EquityN/A-395.3%N/A-179.5%-149.8pp-29.7%
Return on Assets-1082.2%-859.0pp-223.2%+94.2pp-317.3%-181.4pp-136.0%N/A
Current Ratio0.31-1.9x2.21+1.4x0.84-3.4x4.28N/A
Liabilities-to-EquityN/A0.77N/A0.32N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$1.6M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
NeuroSense Therapeutics Ltd. NRSN FY2025 N/A -$11.1M N/A $2.4M —
GRI Bio, Inc. GRI FY2025 N/A -$12.0M N/A $2.4M —
Dermata Therapeutics, Inc. DRMA FY2025 N/A -$7.6M N/A $2.5M —
Purple Biotech Ltd. PPBT FY2025 N/A -$26.4M N/A $2.5M —
Traws Pharma, Inc. TRAW FY2025 $2.8M $9.2M N/A $2.7M 26/100
HCW Biologics Inc. HCWB FY2025 $54K -$8.0M N/A $2.4M —

Frequently Asked Questions

No, NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $11.1M in fiscal year 2025.

NeuroSense Therapeutics Ltd. (NRSN) reported diluted earnings per share of -$0.44 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NeuroSense Therapeutics Ltd. (NRSN) had EBITDA of -$11.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

NeuroSense Therapeutics Ltd. (NRSN) recorded an outflow of $7.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

NeuroSense Therapeutics Ltd. (NRSN) recorded an outflow of $7.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

NeuroSense Therapeutics Ltd. (NRSN) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.

NeuroSense Therapeutics Ltd. (NRSN) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

NeuroSense Therapeutics Ltd. (NRSN) invested $6.2M in research and development during fiscal year 2025.

NeuroSense Therapeutics Ltd. (NRSN) had 33M shares outstanding as of fiscal year 2025.

NeuroSense Therapeutics Ltd. (NRSN) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

NeuroSense Therapeutics Ltd. (NRSN) had a return on assets of -1082.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

NeuroSense Therapeutics Ltd. (NRSN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.4M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

NeuroSense Therapeutics Ltd. (NRSN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.4M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, NeuroSense Therapeutics Ltd. (NRSN) held $166K in cash, cash equivalents and investments, and reported an operating cash outflow of $7.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

NeuroSense Therapeutics Ltd. (NRSN) has negative shareholder equity of -$1.6M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

NeuroSense Therapeutics Ltd. (NRSN) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $11.1M while operations used $7.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top